Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA

Aim: Head-to-head studies of survival outcomes associated with different androgen receptor pathway inhibitor (ARPI) treatments for metastatic castration (hormone)-sensitive prostate cancer have not been conducted. The purpose of this study was to compare 24-month overall survival among ARPI-naive...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Benjamin Lowentritt, Mehmet A Bilen, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Frederic Kinkead, Lilian Diaz, Dominic Pilon, Lorie Ellis, Neal D Shore
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Becaris Publishing Limited 2025-05-01
Schriftenreihe:	Journal of Comparative Effectiveness Research
Schlagworte:	androgen receptor pathway inhibitors comparative effectiveness research prostatic neoplasms
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!